Details of the Drug

General Information of Drug (ID: DMDTC7R)

• Drug Name: Phenindamine
• Synonyms: Fenindamina; Phenindaminum; Phenindiamine; Thephorin; NU 1504; Fenindamina [INN-Spanish]; Nolahist (TN); Phenindamine (INN); Phenindamine [INN:BAN]; Phenindaminum [INN-Latin]; Thephorin (TN); 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-1H-indeno(2,1-c)pyridine; 2,3,4,9-Tetrahydro-2-methyl-9-phenyl-lH-indeno(2,1-c)pyridine; 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lH-indeno-(2,1-c)pyridine; 2-Methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine; 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Common cold	CA00	Approved	[2]
Urticaria	EB00-EB05	Approved	[1]
Vasomotor/allergic rhinitis	CA08	Approved	[1]
Pruritus	EC90	Investigative	[3]

• Therapeutic Class: Antihistamines
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 261.399
  Logarithm of the Partition Coefficient (xlogp); 3.1
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 1
• Chemical Identifiers:
  Formula: C19H19N
  IUPAC Name: 2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
  Canonical SMILES: CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4
  InChI: InChI=1S/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3
  InChIKey: ISFHAYSTHMVOJR-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 11291
  ChEBI ID: CHEBI:8065
  CAS Number: 82-88-2
  DrugBank ID: DB01619
  TTD ID: D06UDO
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[4]

Molecular Expression Atlas of This Drug

• The Studied Disease: Allergic rhinitis
• ICD Disease Classification: CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Phenindamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[5]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[5]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Cariprazine.	Bipolar disorder [6A60]	[6]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Phenindamine when combined with Acetylcholine.	Cataract [9B10]	[7]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[8]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[8]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Phenindamine and OPC-34712.	Depression [6A70-6A7Z]	[6]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Phenindamine and Esketamine.	Depression [6A70-6A7Z]	[9]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[6]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Phenindamine and ITI-007.	Insomnia [7A00-7A0Z]	[6]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Phenindamine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[10]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Phenindamine and Lasmiditan.	Migraine [8A80]	[11]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Phenindamine and Flibanserin.	Mood disorder [6A60-6E23]	[12]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Methylscopolamine.	Peptic ulcer [DA61]	[6]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Iloperidone.	Schizophrenia [6A20]	[6]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Thiothixene.	Schizophrenia [6A20]	[6]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Asenapine.	Schizophrenia [6A20]	[6]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Phenindamine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[5]

References

• [1] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [2] Drug information of Phenindamine, 2008. eduDrugs.
• [3] An evaluation of thephorin as an adjunct in the treatment of pruritic dermatoses. N C Med J. 1949 Sep;10(9):476-9.
• [4] The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60.
• [5] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [6] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [7] Multum Information Services, Inc. Expert Review Panel.
• [8] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [9] Cerner Multum, Inc. "Australian Product Information.".
• [10] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [11] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [12] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.